Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer

被引:0
|
作者
Zhang, Leiming [1 ,2 ]
Yu, Zehao [2 ]
Jin, Rong [1 ,2 ]
Yang, Xuanang [2 ]
Ying, Dongjian [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Minimally Invas Surg, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Postoperative; Model prediction; DUCTAL ADENOCARCINOMA; SURGERY; 5-FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CONSENSUS; THERAPY;
D O I
10.1007/s00432-023-05071-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSurgery represents a primary therapeutic approach for borderline resectable and locally advanced pancreatic cancer (BR/LAPC). However, BR/LAPC lesions exhibit high heterogeneity and not all BR/LAPC patients who undergo surgery can derive beneficial outcomes. The present study aims to employ machine learning (ML) algorithms to identify those who would obtain benefits from the primary tumor surgery.MethodsWe retrieved clinical data of patients with BR/LAPC from the Surveillance, Epidemiology, and End Results (SEER) database and classified them into surgery and non-surgery groups based on primary tumor surgery status. To eliminate confounding factors, propensity score matching (PSM) was employed. We hypothesized that patients who underwent surgery and had a longer median cancer-specific survival (CSS) than those who did not undergo surgery would certainly benefit from surgical intervention. Clinical and pathological features were utilized to construct six ML models, and model effectiveness was compared through measures such as the area under curve (AUC), calibration plots, and decision curve analysis (DCA). We selected the best-performing algorithm (i.e., XGBoost) to predict postoperative benefits. The SHapley Additive exPlanations (SHAP) approach was used to interpret the XGBoost model. Additionally, data from 53 Chinese patients prospectively collected was used for external validation of the model.ResultsAccording to the results of the tenfold cross-validation in the training cohort, the XGBoost model yielded the best performance (AUC = 0.823, 95%CI 0.707-0.938). The internal (74.3% accuracy) and external (84.3% accuracy) validation demonstrated the generalizability of the model. The SHAP analysis provided explanations independent of the model, highlighting important factors related to postoperative survival benefits in BR/LAPC, with age, chemotherapy, and radiation therapy being the top three important factors.ConclusionBy integrating of ML algorithms and clinical data, we have established a highly efficient model to facilitate clinical decision-making and assist clinicians in selecting the population that would benefit from surgery.
引用
收藏
页码:11857 / 11871
页数:15
相关论文
共 50 条
  • [41] Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival
    Panda, Ananya
    Garg, Ishan
    Truty, Mark J.
    Kline, Timothy L.
    Johnson, Matthew P.
    Ehman, Eric C.
    Suman, Garima
    Anaam, Deema A.
    Kemp, Bradley J.
    Johnson, Geoffrey B.
    Halfdanarson, Thorvardur R.
    Venkatesh, Sudhakar K.
    Fidler, Jeff L.
    Goenka, Ajit H.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2021, 217 (03) : 730 - 740
  • [42] Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
    Maggino, Laura
    Malleo, Giuseppe
    Marchegiani, Giovanni
    Viviani, Elena
    Nessi, Chiara
    Ciprani, Debora
    Esposito, Alessandro
    Landoni, Luca
    Casetti, Luca
    Tuveri, Massimiliano
    Paiella, Salvatore
    Casciani, Fabio
    Sereni, Elisabetta
    Binco, Alessandra
    Bonamini, Deborah
    Secchettin, Erica
    Auriemma, Alessandra
    Merz, Valeria
    Simionato, Francesca
    Zecchetto, Camilla
    D'Onofrio, Mirko
    Melisi, Davide
    Bassi, Claudio
    Salvia, Roberto
    JAMA SURGERY, 2019, 154 (10) : 932 - 942
  • [43] Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy
    Addeo, Pietro
    Rosso, Edoardo
    Fuchshuber, Pascal
    Oussoultzoglou, Elie
    De Blasi, Vito
    Simone, Gael
    Belletier, Christine
    Dufour, Patrick
    Bachellier, Philippe
    ONCOLOGY, 2015, 89 (01) : 37 - 46
  • [44] Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma
    Temraz, Sally
    Nassar, Farah
    Hammoud, Miza Salim
    Mukherji, Deborah
    O'Reilly, Eileen M.
    Dbouk, Haifa
    Farhat, Fadi
    Charafeddine, Maya
    Faraj, Walid
    Khalifeh, Mohammad J.
    Abou-Alfa, Ghassan K.
    Shamseddine, Ali
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 735 - 742
  • [45] Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer? A Systematic Review
    Saha, Animesh
    Wadsley, Jonathan
    Sirohi, Bhawna
    Goody, Rebecca
    Anthony, Alan
    Perumal, Karthikeyan
    Ulahanan, Danny
    Collinson, Fiona
    PANCREAS, 2023, 52 (01) : E7 - E20
  • [46] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [47] Multimodal survival prediction in advanced pancreatic cancer using machine learning
    Keyl, J.
    Kasper, S.
    Wiesweg, M.
    Goetze, J.
    Schoenrock, M.
    Sinn, M.
    Berger, A.
    Nasca, E.
    Kostbade, K.
    Schumacher, B.
    Markus, P.
    Albers, D.
    Treckmann, J.
    Schmid, K. W.
    Schildhaus, H-U
    Siveke, J. T.
    Schuler, M.
    Kleesiek, J.
    ESMO OPEN, 2022, 7 (05)
  • [48] Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer
    Xu, Xifeng
    Wu, Qiong
    Wang, Zhen
    Zheng, Song
    Ge, Ke
    Jia, Changku
    CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 19 (01) : 149 - 157
  • [49] Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer A Single Institution Experience
    Rangelova, Elena
    Wefer, Agnes
    Persson, Saga
    Valente, Roberto
    Tanaka, Kimitaka
    Orsini, Nicola
    Segersvard, Ralf
    Arnelo, Urban
    Del Chiaro, Marco
    ANNALS OF SURGERY, 2021, 273 (03) : 579 - 586
  • [50] Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
    Heinrich, Stefan
    Besselink, Marc
    Moehler, Markus
    van Laethem, Jean-Luc
    Ducreux, Michel
    Grimminger, Peter
    Mittler, Jens
    Lang, Hauke
    Lutz, Manfred P.
    Lesurtel, Mickael
    BMC CANCER, 2019, 19 (1)